United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
Business Wire•17/08/2026•07:00 ET
0
Whiz Insights
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
Approximately 200,000 patients in the United States have PPF, with limited treatment options
Get started
Create a free account to read the full story.